Keyword Analysis & Research: chimerix
Keyword Research: People who searched chimerix also searched
Search Results related to chimerix on Search Engine
-
Chimerix | Innovative medicines for cancer and other serious …
https://www.chimerix.com/
webFeb 29, 2024 · Chimerix’s mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. Learn more about our approach to investing in novel drug candidates that meaningfully improve the probability of survival and the collaborative team driving the development of these promising new therapies.
DA: 3 PA: 75 MOZ Rank: 41
-
Who We Are - Chimerix : Chimerix
https://www.chimerix.com/about-us/who-we-are/
webScientists and doctors revolutionizing therapies for difficult diseases. At Chimerix, we are on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. With a current focus in oncolog y, we are devoted to filling gaps in the treatment paradigm.
DA: 2 PA: 40 MOZ Rank: 77
-
Our Pipeline - Chimerix : Chimerix
https://www.chimerix.com/our-pipeline/
webONC201. H3 K27M-mutant glioma (orphan drug designation) ONC201. Neuroendocrine Tumors (PCPG) ONC206. Solid tumors. CMX521. SARS-CoV-2 (COVID-19) ONC212.
DA: 80 PA: 13 MOZ Rank: 53
-
Chimerix, Inc. (CMRX) Stock Price, News, Quote & History - Yahoo Finance
https://finance.yahoo.com/quote/CMRX
webQ4 2023 Chimerix Inc Earnings Call. Find the latest Chimerix, Inc. (CMRX) stock quote, history, news and other vital information to help you with your stock trading and investing.
DA: 45 PA: 64 MOZ Rank: 88
-
Leadership - Chimerix : Chimerix
https://www.chimerix.com/about-us/leadership/
webMr. Andriole became President, CEO and a member of the Board of Directors of Chimerix in August 2023. Prior to becoming President and CEO, Mr. Andriole was Chimerix’s Chief Business Officer and CFO from 2019 to 2023 during which time he led key strategic acquisitions, divestitures and capital raising transactions which reprioritized Chimerix ...
DA: 59 PA: 51 MOZ Rank: 66
-
Investor Relations | Chimerix, Inc.
https://ir.chimerix.com/
webFeb 22, 2024 · Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update. Form 10-K. Investor website contains information about our business for stockholders, potential investors, and financial analysts.
DA: 30 PA: 92 MOZ Rank: 91
-
Leadership - Board of Directors - Chimerix : Chimerix
https://www.chimerix.com/about-us/leadership-board-of-directors/
webMarc Kozin joined the board of directors for Chimerix in March 2024. Mr. Kozin brings more than 35 years of experience in corporate and business strategy consulting, merger and acquisition advisory services, and value management.
DA: 21 PA: 23 MOZ Rank: 82
-
Press Releases | Chimerix, Inc.
https://ir.chimerix.com/press-releases
webDURHAM, N.C. , Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on.
DA: 74 PA: 1 MOZ Rank: 98
-
Chimerix Announces Data Highlighting Clinical Efficacy and …
https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-data-highlighting-clinical-efficacy-and
webAug 16, 2023 · Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front- Line Setting, Post Radiation, Versus 12 Months mOS Historical Control. ONC201 Treatment Disrupts Key Metabolic and Epigenetic Pathways. DURHAM, N.C., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a …
DA: 7 PA: 49 MOZ Rank: 66
-
About Us - Chimerix : Chimerix
https://www.chimerix.com/about-us/
webOur Pipeline. Our PipelineOur Pipeline. Oncology: Imipridones. ONC201 dordavipronefor gliomas. ONC206for central nervous system tumors. ONC212IND-enabling studies. PublicationsPresentationsNeuro Oncology Publications. Company. Who We Are.
DA: 79 PA: 91 MOZ Rank: 74